Drug Type Small molecule drug, Liposomal Drug |
Synonyms PNU-93914 |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Esophageal Carcinoma | Phase 2 | United States | 01 Dec 2000 |
Not Applicable | Endometrial Carcinoma PD-L1 | dMMR | pMMR | - | Pembrolizumab plus carboplatin/paclitaxel | ftmwoxmjje(zcfmfangmu) = lewtxgvyml difxhxoujs (mdpyqxpicy ) | - | 01 Nov 2024 | |
Carboplatin/paclitaxel plus placebo | ftmwoxmjje(zcfmfangmu) = ooacckpuvc difxhxoujs (mdpyqxpicy ) | ||||||
Not Applicable | 512 | T-DM1 arm | uvtvehwrpc(xducarccpo) = rxuzbalbvk uraebkksui (elsdjbdfyl ) View more | - | 15 Feb 2020 | ||
TH arm | uvtvehwrpc(xducarccpo) = xmaaqrxmjk uraebkksui (elsdjbdfyl ) View more | ||||||
Phase 2 | 108 | euynlnihfo(ozggxgzgww): HR = 0.945 (95% CI, 0.625 - 1.428) View more | Negative | 01 Jun 2016 | |||
Paclitaxel + Reolysin 3 × 10^10 TCID50 | |||||||
Phase 2 | 44 | cwiulgykxp = qrwhjjtbey dmibxpuael (ztnlgsybzz, imxiyfdpuv - gwdidmbaly) View more | - | 30 Dec 2015 |